Vir Biotechnology says VIR-5500 received FDA fast track designation for prostate cancer
VIR•Vir Biotechnology said its PSMA-targeted T-cell engager VIR-5500 received FDA fast track designation for prostate cancer. Phase 3 trials are anticipated to begin in 2027.
1. Fast track designation
Vir Biotechnology said the FDA granted fast track designation to VIR-5500, its PSMA-targeted Pro-Xten dual-masked T-cell engager, for the treatment of prostate cancer. The company anticipates beginning Phase 3 trials in 2027.
